A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis.
Nicolas CollonguesGuillaume BeckerValérie JolivelEstelle Ayme-DietrichJérôme de SezeFabien BinaméChristine Patte-MensahLaurent MonassierAyikoé Guy Mensah-NyaganPublished in: Neurology and therapy (2022)
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) resulting in demyelination and neurodegeneration. The therapeutic strategy is now largely based on reducing inflammation with immunosuppressive drugs. Unfortunately, when disease progression is observed, no drug offers neuroprotection apart from its anti-inflammatory effect. In this review, we explore current knowledge on the assessment of neurodegeneration in MS and look at putative targets that might prove useful in protecting the axon from degeneration. Among them, Bruton's tyrosine kinase inhibitors, anti-apoptotic and antioxidant agents, sex hormones, statins, channel blockers, growth factors, and molecules preventing glutamate excitotoxicity have already been studied. Some of them have reached phase III clinical trials and carry a great message of hope for our patients with MS.
Keyphrases
- multiple sclerosis
- anti inflammatory
- phase iii
- clinical trial
- oxidative stress
- white matter
- open label
- mass spectrometry
- brain injury
- phase ii
- ms ms
- cerebral ischemia
- healthcare
- double blind
- drug induced
- spinal cord injury
- cell death
- blood brain barrier
- optic nerve
- randomized controlled trial
- emergency department
- angiotensin converting enzyme
- study protocol
- type diabetes
- adverse drug
- chronic myeloid leukemia
- optical coherence tomography